BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $919,736 | -83.9% | 53,473 | -84.4% | 0.00% | -88.0% |
| Q1 2023 | $5,699,955 | +433.0% | 343,785 | +144.9% | 0.02% | +316.7% |
| Q4 2022 | $1,069,482 | -6.4% | 140,352 | +22.1% | 0.01% | -14.3% |
| Q3 2022 | $1,143,000 | +305.3% | 114,955 | +579.1% | 0.01% | +250.0% |
| Q4 2021 | $282,000 | -80.9% | 16,928 | -29.4% | 0.00% | -91.3% |
| Q1 2021 | $1,477,000 | +523.2% | 23,985 | +279.9% | 0.02% | +666.7% |
| Q3 2020 | $237,000 | -45.1% | 6,314 | -52.4% | 0.00% | -50.0% |
| Q2 2020 | $432,000 | – | 13,251 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |